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The cyclolignan picropodophyllin attenuates
intimal hyperplasia after rat carotid balloon injury
by blocking insulin-like growth factor-1 receptor
signaling
Anton Razuvaev, MD,a Bimma Henderson, MD,a Leonard Girnita, MD, PhD,b
Olle Larsson, MD, PhD,b Magnus Axelson, MD, PhD,a Ulf Hedin, MD, PhD,a
and Joy Roy, MD, PhD,a,c Stockholm, Sweden
Objective: Smooth muscle cell proliferation (SMC) is a pivotal factor in the development of intimal hyperplasia after
vascular injury. A number of growth factors, including insulin-like growth factor-1 (IGF-1), have been shown to be
involved in SMC proliferation. We evaluated the effect of picropodophyllin (PPP), a new IGF-1 receptor inhibitor, in the
prevention of SMC proliferation and development of intimal hyperplasia after vascular injury.
Methods: The effects of systemic administration of PPP on intimal hyperplasia were studied in a balloon rat carotid injury
model. Lesions were quantified by morphometry and SMC proliferation and apoptosis was studied by immunohisto-
chemical staining for proliferating cell nuclear antigen (PCNA) and activated caspase 3, respectively. The effect of PPP on
rat aortic SMC proliferation and apoptosis was studied in vitro by using cell counting, 3[H]-thymidine incorporation,
and a flow cytometry assay for annexin V. Phosphorylation of the IGF-1 receptor, protein kinase B (Akt), and
extracellular signal-regulated kinase 1/2 (ERK1/2) in vitro and in vivo were analyzed by using Western blotting.
Results: PPP inhibited IGF-1–mediated SMC proliferation in vitro but no significant increase in apoptosis was detected.
In rats treated with PPP, a more than a twofold reduction in carotid intima area was observed 2 weeks after balloon
injury, a significant decrease in PCNA staining was demonstrated in early lesions, but activated caspase 3 was not detected.
In addition, PPP attenuated phosphorylation of the IGF-1 receptor, Akt, and ERK1/2 in IGF-1–stimulated SMCs in
vitro, and a reduced phosphorylation of the IGF-1 receptor and Akt was found in balloon-injured carotid arteries in rats
treated with PPP.
Conclusion: These results show that PPP potently blocks IGF-1–mediated phosphorylation of the IGF-1 receptor in
SMCs, decreases downstreamAkt and ERK1/2 activation, inhibits SMC replication, and subsequently attenuates intimal
hyperplasia after balloon injury of rat carotid arteries. ( J Vasc Surg 2007;46:108-15.)
Clinical Relevance: Intimal hyperplasia remains a major obstacle to vessel patency after vascular surgery. Although the
role of various growth factors, including insulin-like growth factor-1 (IGF-1), has been studied in the development of
intimal hyperplasia, no clinical therapy has emerged to date. IGF-1, either from the systemic circulation or locally
produced by smooth muscle cells (SMCs) after vascular injury, binds to its receptor (IGF-1R) on SMCs and leads to
activation of a number of signaling pathways known to be involved in SMC proliferation and survival. Drugs that
specifically inhibit activation of IGF-1R without affecting the insulin receptor have previously not been available. In this
study, we used picropodophyllin, a newly developed and highly specific IGF-1R inhibitor, to investigate the therapeutic
potential of targeting the IGF-1 axis in the prevention of intimal hyperplasia after vascular injury.From the Department of Molecular Medicine and Surgery,a Karolinska
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108Restenosis and vein graft stenosis are major clinical compli-
cations after interventional vascular procedures and are
attributed to vessel recoil, early thrombus formation, and
intimal hyperplasia.1 Proliferation of smooth muscle cells
(SMCs) plays a critical role in neointima formation, and a
number of mitogens are also involved, including platelet-
derived growth factor (PDGF), basic fibroblast growth
factor (bFGF), and insulin-like growth factor-1 (IGF-1).2-5
IGF-1 has been shown to have mitogenic, antiapop-
totic, and promigratory effects on vascular SMCs.2 It binds
to the SMC IGF-1 receptor (IGF-1R), which initiates
signaling in multiple pathways, including phosphatidylino-
sitol-3 (PI-3) kinase and Ras/mitogen-activated protein
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(mRNA) levels are increased in de novo and in restenotic
coronary lesions compared with normal coronary arteries.3
In addition, neointimal hyperplasia develops in transgenic
mice overexpressing IGF-1.4 Thrombin, PDGF, bFGF,
angiotensin II, and estrogen have been shown to influence
the levels of IGF-1 and IGF-1R mRNA in vascular SMCs.2
Taken together, these observations suggest a role for IGF-1
in proliferation, migration, and inhibition of apoptosis in
SMCs during restenosis development.5 The IGF-1 axis has
been targeted in animal models, using both pharmacother-
apy and genetic approaches to prevent SMC proliferation
and intimal hyperplasia.6-8 So far, however, no clinical
studies using drugs that affect the IGF-1/IGF-1R pathway
have shown any benefit.9,10
In parallel, IGF-1 and IGF-1R have been objects of
interest in the field of cancer research. IGF-1R is overex-
pressed in many cancers, and IGF-1 is believed to play a
critical role in the development and progression of human
cancer.11 Among different attempts to block IGF-1R acti-
vation in cancer, the cyclolignan picropodophyllin (PPP)
has been found to be a highly specific inhibitor of IGF-1R
phosphorylation without affecting the insulin receptor.11
The inhibitory effects of PPP on IGF-1R phosphorylation
and on malignant cell growth have been studied both in
vitro and in vivo,12-14 and PPP treatment has been shown
to cause tumor regression in several mouse cancer mod-
els.14,15 The aim of this study was to determine whether
pharmacologic therapy with PPP aimed at preventing
IGF-1R activation could affect neointimal formation after
vascular injury.
MATERIALS AND METHODS
Reagents. PPP was synthesized as previously de-
scribed,16 and its purity after recrystallization was 99.7%.
For experimental purposes, PPP was dissolved in ethanol
(0.5 mmol/L) before addition to cell cultures or dimethyl
sulfoxide (DMSO; 0.5 mmol/L) for in vivo experiments.
Recombinant IGF-1 and PDGF-BB were from Invitro-
gen Life Technologies (Invitrogen Corporation, Carlsbad,
Calif). Cell culture reagents and media were from Gibco,
(Invitrogen Corp), unless specifically stated. Collagenase
type 2 (207 U/mg) was from Worthington Biochemical
Corporation (Lakewood, NJ), and 3[H] thymidine was
from Amersham Biosciences (Piscataway, NJ).
Rabbit polyclonal antibodies against protein kinase B
(Akt) and phospho-Akt were from Upstate Cell Signaling
Solutions (Temecula, Calif). Polyclonal IGF-1R antibodies
(C-20 and H-60) and a monoclonal antibody to phospho-
tyrosine (PY99) were from Santa Cruz Biotechnology Inc
(Santa Cruz, Calif). Antibodies against activated caspase 3,
phospho-extracellular signal-regulated kinase (pERK) and
(ERK) were from Cell Signaling Technology (Danvers,
Mass). Antibodies against proliferating cellular nuclear an-
tigen (PCNA) were from DakoCytomation (Glostrup,
Denmark).
Pharmacokinetics. All animal experiments were per-
formed according to protocols approved by the RegionalAnimal Ethic Committee, Stockholm, and institutional
guidelines and protocols for animal care were followed.
Two groups (3 rats in each group) of male Sprague-Dawley
rats (B&K, Sollentuna, Sweden), weighing 400 grams,
were used to determine the appropriate dose and interval of
PPP administration.
Rats were intraperitoneally injected with 0.2 mL of a
100-mmol/L PPP (20 micromols) solution consisting of
DMSO and sunflower oil (9:1). The rats in the first group
were injected only once, and blood samples were collected
from the lateral tail vein after 2, 4, 8, and 12 hours. The rats
in the second group received two injections, one at time 0
and one after 12 hours. Blood samples were collected from
the lateral tail vein 14, 16, 20, and 24 hours after the first
injection. Isoflurane anesthesia was used for all procedures.
Levels of PPP in the plasma or serum samples were
determined by reversed-phase high-performance liquid
chromatography and ultraviolet detection (254 nm) after
extraction and purification of PPP on small octadecylsilane-
bonded silica columns. As summarized in Table I, treat-
ment with 20 mol of PPP (8 mg  20 mg/kg body
weight) every 12 hours was enough to keep the plasma
concentration of PPP 200 nmol/L, a concentration pre-
viously found to inhibit cancer growth in mice.12
Rat carotid injury model and drug treatment. Male
Sprague-Dawley rats (300 to 400 grams) were anesthetized
with inhalation of 2% isoflurane. As previously described,17
the left common, external, and internal arteries were ex-
posed, and a 2F Fogarty balloon embolectomy catheter
(Edwards Lifesciences Corp, Irvine, Calif) was inserted
through an external carotid arteriotomy. The catheter was
advanced to the common carotid artery, inflated with sa-
line, and withdrawn three times with rotation.
The study animals were treated with 0.2 mL PPP
dissolved in DMSO or sunflower oil at a concentration of
100 mmol/L injected intraperitoneally (n  7). The con-
trol group (n  6) was injected with same volume of
DMSO/sunflower oil solution. Drugs were administered
Table I. Serum concentration of rats treated with
picropodophyllin*
Time after first
injection
(hours)
PPP concentration (mol/L)
Group 1 Group 2
2 5.00 ND
4 4.45 ND
8 1.95 ND
14 ND 3.50
16 ND 4.05
20 ND 1.77
24 0.53 2.23
48 ND 0.48
PPP, Picropodophyllin; ND, not done.
*Group 1 rats were treated with one intraperitoneal injection of 20 mol
PPP. Group 2 rats were treated with two intraperitoneal injections, 12 hours
apart. The serumwas pooled from two or three rats, and PPP concentrations
were determined by using high-performance liquid chromatography.under isoflurane anesthesia every 12 hours, starting 12
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treatment were observed in the animals.
Histomorphometric analysis. After 14 days, the rats
were anesthetized and perfusion-fixed with 4% formalde-
hyde. The left and right carotid arteries were retrieved and
placed in the same fixative. Samples were then embedded in
paraffin, sectioned (5 m), and sections were stained with
Masson Trichrome (Sigma-Aldrich Sweden AB, Stock-
holm, Sweden). Images were taken using Nikon Eclipse
E800 microscope with Nikon DXM1200 digital camera
(NikonCorp, Kawasaki, Kanagawa, Japan). Cross-sectional
areas of the lumen, neointima (from the internal elastic
lamina to the lumen), and media were determined using
Able Image Analyser (MuLabs, Ljubljana, Slovenia). The
intima-to-media ratio was then calculated from the deter-
mined means (Table II). Three sections from each vessel
were analyzed.
Immunohistochemical staining. Six rats underwent
balloon injury and were treated with PPP or vehicle for 4
days. After 4 days, the carotid arteries were prepared for
sectioning in paraffin blocks. After sectioning, the slides
were stained by using a standard protocol, as previously
described.18 Primary antibodies against PCNA and acti-
vated caspase 3 were used to estimate cell proliferation and
apoptosis, respectively, and staining of intestinal epithelium
was used as positive control.
Cell culture. Rat aortic SMCs were isolated, as previ-
ously described,19 Cells were cultured in Ham’s F-12 me-
dium supplemented with 10% fetal bovine serum (FBS), 50
g/mL L-ascorbic acid, 50 g/mL streptomycin, 50
IU/mL penicillin (F-12/10% FBS), and were used in
experiments after two to six passages. The highest concen-
tration of ethanol in the incubation media, used to dissolve
PPP or as a vehicle, was 0.05%.
Cell proliferation and thymidine incorporation as-
says. SMCs were seeded in 24-well plates, serum-deprived
for 48 hours, treated with 10 ng/mL IGF-1 or 10% FBS,
and treated with 0.05 or 0.25 mol/L PPP. Cells were
counted for up to 4 days of stimulation using a cell counter
(Analys Instrument AB, Bromma, Sweden). DNA synthesis
was estimated after 24 hours using a 3[H]-thymidine incor-
Table II. Morphometric analysis of cross-sections of carot
picropodophyllin-treated rats
Injured*
Sham PPP
Area in mm2
Lumen 0.24  0.041 0.295  0.046
Intima (I) 0.144  0.026 0.067  0.035
Media (M) 0.131  0.013 0.123  0.016
Tota 0.515  0.061 0.485  0.051
I/M ratio 1.099  0.149 0.543  0.249
PPP, Picropodophyllin; NA, not applicable.
*Data are shown as mean  SD.
†Significance at P  .05.poration assay, as previously described.20Determination of apoptosis in vitro. Apoptosis was
determined using a flow cytometric Annexin V binding
assay according to the manufacturer’s instructions (BD
Pharmingen, San Diego, Calif). Briefly, SMCs grown in
12-well plates in either 10% FBS or 30 ng/mL IGF-1 in the
presence or absence of 0.25 mol/L PPP, were trypsinized
after 48 hours, washed twice with cold phosphate-buffered
saline (PBS), resuspended in binding buffer containing 10
mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid/sodium hydroxide (pH 7.4), 140 mmol/L sodium
chloride, and 2.5 mmol/L calcium chloride, and incubated
with 5L fluorescein isothiocyanate-labeled annexin V and
10 L propidium iodide (stock solution, 50 g/mL) for
15 minutes in the dark at room temperature. The cells were
analyzed by flow cytometry (FACScan, Becton Dickinson,
San Jose, Calif). SMCs positive for annexin V were re-
garded to undergo apoptosis, and the subgroup of annexin
V positive cells that were negative for propidium iodide
were considered to be in early apoptosis.
Western blot analysis. SMCs cultured in six-well
plates were starved for 48 hours in F-12/0.1% bovine
serum albumin. After treatment with PPP in concentrations
0.05, 0.25, and 2.5 mol/L or 100 mol/L Wortmannin
for 1 hour, SMCs were stimulated with 50 ng/mL of IGF-I
or 10 g/mL PDGF-BB for up to 45 minutes. The cells
were then rinsed with PBS and lysed with 500 L of lysis
buffer (50 mmol Tris-HCl, pH 7.4; 1% NP-40; 0.25%
sodium deoxycholate; 150 mmol/L sodium chloride; 1
mmol/L ethylenediaminetetraacetic acid; 1 mmol phenyl-
methylsulfonyl fluoride, 1g/mL each aprotinin, leupep-
tin, pepstatin; 1 mmol/L sodium orthovanadate, and 1
mmol sodium fluoride) and supplemented with protease
inhibitors (mini protease inhibitor cocktail tablet, Roche,
Basel, Switzerland). The proteins were then prepared and
Western blotting performed, as previously described.19
The Western blotting experiments were repeated three
times.
For in vivo experiments, six rats were treated with PPP
or control solution, starting treatment 12 hours before
surgery as described, when the left CCA was exposed to
balloon injury. After 2 days, the animals were euthanized,
teries 14 days after injury obtained from sham or
Not injured*
P Sham PPP P
042† 0.341  0.101 0.352  0.033 .823
001† NA NA NA
323 0.104  0.022 0.105  0.013 .926
374 0.444  0.122 0.456  0.042 .840
001† NA. NA NAid ar
.
.
.
.
.and the arteries were dissected and snap frozen in liquid
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noprecipitation buffer and the proteins analyzed by using
Western blotting. To immunoprecipitate IGF-1R protein,
15 L Protein G Plus-A/G agarose and 1g antibody were
added to 1g of protein material. After overnight incuba-
tion at 4°C on a rocker platform, the immunoprecipitates
were collected by centrifugation in a microcentrifuge at
2500 rpm for 2 minutes. The supernatant was discarded,
whereupon the pellet was washed and then dissolved in a
sample buffer for sodium dodecyl sulfate polyacrylamide
gel electrophoresis.
Statistical analysis. To detect significant differences
between the histomorphometric data of the two groups,
the data were analyzed with the two-sided Student t test
and presented as mean  the standard deviation. When
differences were compared between multiple groups, the
data were analyzed with one-way analysis of variance and
the Bonferroni multiple comparison test, using GraphPad
Prism software (GraphPad, San Diego, Calif). A P  .05
was considered significant.
RESULTS
Picropodophyllin attenuates intimal hyperplasia.
PPP treatment significantly reduced intimal hyperplasia and
increased lumen area in carotid arteries 2 weeks after bal-
loon injury. Compared with the control group, which only
received the vehicle, animals treated with PPP showed a
reduction of intima/media ratio by 50% (Fig 1, A and B;
Table II).
Immunohistochemical staining showed a decrease in
PCNA-positive nuclei in PPP-treated animals 4 days after
balloon injury (Fig 1, C). In contrast, no or very little
staining for activated caspase 3 was observed in early lesions
in PPP-treated or control animals, indicating minor, if any,
effect of PPP on apoptosis in the vessel wall early after
balloon injury (data not shown).
Effects of picropodophyllin on smooth muscle cell
proliferation and apoptosis in cell culture. To study the
mechanisms behind the observed ability of PPP to reduce
intimal hyperplasia, the effect of PPP treatment on SMC
proliferation in vitro was analyzed. PPP treatment was
found to significantly decrease cell number after 4 days in
cultures stimulated with 10 ng/mL IGF-1. PPP treatment
also reduced cell number in cultures treated with 10% FBS,
but the effect was less pronounced (Fig 2, A).
To assess the contribution of cell cycle arrest or apo-
ptosis to the decrease in cell number, DNA synthesis and
apoptosis in cultured SMCs were estimated. PPP signifi-
cantly inhibited DNA synthesis in cells stimulated with 10
ng/mL IGF-1 or with 10% FBS (Fig 2, B). Estimation of
annexin V binding 48 hours after stimulation with 30
ng/mL IGF-1 or 10% FBS in the presence or absence of
0.25 mol/L PPP showed an increase in the percentage of
apoptotic cells by PPP treatment in SMCs stimulated with
IGF-1 and FBS; however, statistical significance was not
achieved (Fig 3).
Picropodophyllin blocks signaling in smooth mus-
cle cells mediated by insulin-like growth factor-1R. Todetermine the effects of PPP treatment on signal transduc-
tion, we studied IGF-1R and Akt phosphorylation in vivo
after balloon injury and in cultured SMCs. In contrast to
noninjured arteries, IGF-1R was phosphorylated after bal-
loon injury and could be effectively blocked by PPP treat-
ment (Fig 4, A). Akt, a downstream substrate of PI-3 kinase
that is activated by IGF-1R stimulation,11 was also phos-
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Fig 1. A, Effects of picropodophyllin (PPP) on neointima forma-
tion after balloon injury. Photomicrographs show cross-sections of
rat carotid arteries 2 weeks after injury.Arrow points to the internal
elastic lamina (IEL); arrowhead points to the external elastic
lamina (EEL).B,Morphometric quantification of the effect of PPP
treatment (n  7; control, n  6) on neointima formation pre-
sented as changes in intima-to-media ratio (left panel) and lumen
area (right panel). Data are shown as mean  SD (*P  .05; **P
 .001).C,Quantification of cells positive for proliferating cellular
nuclear antigen (PCNA) on day 4 after balloon injury (n  3 in
each group). Data are shown as median  SD (P  .05).phorylated in injured arteries, but this response was effi-
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PPP decreased IGF-1R phosphorylation in a dose depen-
dent manner and also blocked Akt activation (Fig 4, B).
To show that the effect of PPP was specific, we stimu-
lated cells with PDGF for 5 minutes in the presence or
absence of PPP. PPP did not affect Akt phosphorylation in
PDGF treated cells, whereas wortmannin, an inhibitor of
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Fig 2. Effect of picropodophyllin (PPP) on smooth muscle cell
(SMC) proliferation. SMC cultures were synchronized in F-12/
0.1% bovine serum albumin, stimulated with 10 ng/mL insulin-
like growth factor-1 (IGF-1), or 10% fetal bovine serum (FBS), in
the presence or absence of PPP. A, Cell number and B, 3[H]
thymidine incorporation were determined as described in “Meth-
ods.” Controls were treated with mitogen only (white bar). Data
are shown as mean  SD (*P  .05, **P  .001).
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Fig 3. Effect of picropodophyllin (PPP) on apoptosis in smooth
muscle cells (SMCs) SMC cultures were synchronized in F12/
0.1% bovine serum albumin, stimulated with 30 ng/mL insulin-
like growth factor-1 (IGF-1) or 10% fetal bovine serum (FBS) in
the presence or absence of PPP, and annexin V labelling deter-
mined by flow cytometry as described inMethods.A,Cells positive
for annexin V and negative for propidium iodide (early apoptosis).
B,Cells all positive for annexin V (total apoptosis). Data are shown
as mean  SD of three experiments (P .05).the PI-3 kinase pathway, blocked Akt activation afterPDGF stimulation (Fig 5, A). ERK1/2 was activated by
both IGF-1 and PDGF; however, IGF-1 stimulation led to
a shorter and less pronounced ERK1/2 activation com-
pared with PDGF. PPP treatment decreased ERK1/2 ac-
tivation after 15minutes in cells treated with IGF-1 but not
with PDGF (Fig 5, B).
DISCUSSION
SMC proliferation is a key element in the development
of intimal hyperplasia,21 and IGF-1 has been shown to be a
potent SMC mitogen. In this study, the cyclolignan PPP,
an IGF-lR inhibitor, was tested to further elucidate the role
of IGF-l in neointimal formation. PPP is nontoxic and
specifically inhibits tyrosine autophosphorylation at sites
Y1135 and Y1136 of the IGF-1R but not of the highly
homologous insulin receptor.12,22 PPP attenuated intimal
hyperplasia after balloon injury in the rat carotid artery,
B
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pAkt
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Fig 4. The effects of picropodophyllin (PPP) on phosphorylation
of insulin-like growth factor-1R (IGF-1R) and protein kinase B
(Akt) in (A) balloon-injured carotid arteries and (B) cultured
smooth muscle cells SMCs. A, Six arteries were retrieved 2 days
after injury, and proteins were isolated for Western blotting using
antibodies against IGF-1R, phosphorylated IGF-1R (pIGF-1R),
phosphorylated Akt (pAkt), and Akt as described in “Methods.”
IGF-1R and Akt phosphorylation was only induced after injury and
was blocked by PPP treatment. B, In IGF-1–stimulated SMC
cultures, PPP decreased IGF-1R and Akt phosphorylation in a
dose-dependent manner with no effect on total Akt expression.prevented IGF-1R phosphorylation and IGF-1R–mediated
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early lesions and in cultured SMCs stimulated with IGF-1.
Studies have shown IGF-1 and IGF-1R expression is
increased in intimal hyperplasia in restenotic arteries.3,23
Furthermore, targeted overexpression of IGF-1 in SMCs
and injury in a transgenic mice model overexpressing IGF-l
showed excessive SMC hyperplasia.4 IGF-l, alone or in
synergy with other growth factors, promotes cell prolifera-
tion in cell culture.11,15 A major signaling pathway acti-
vated by IGF-1 is the PI-3 kinase/Akt pathway.11 In our
study, PPP treatment decreased IGF-IR and downstream
Akt phosphorylation and also suppressed MAPK/ERK sig-
naling as demonstrated by decreased ERK1/2 phosphory-
lation in SMCs stimulated with IGF-1. In support of this
finding, PPP has previously been shown to decrease ERK
activation in IGF-l–stimulated cell lines.13,17
Because thymidine incorporation and PCNA positive
cells were decreased by PPP treatment, we conclude that
PPP affects the G1-S phase transition in proliferating
SMCs. IGF-lR inactivation by PPP decreased SMC prolif-
eration after IGF -1 and serum stimulation. Serum contains
a number of other growth factors in addition to IGF-l, and
some of these may act through the IGF-l pathway,24-27
either by transactivation of IGF-lR or by stimulating syn-
thesis and release of IGF-l.25 PPP significantly decreased
cell proliferation in serum-stimulated cell but did not affect
activation of Akt or ERK1/2 after PDGF stimulation. This
finding suggests that PPP does not interfere with the early
PDGF
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Fig 5. The effects of picropodophyllin (PPP) on phosphorylation
of protein kinase B (Akt) and extracellular signal-regulated kinase
(ERK) in cultured smooth muscle cells. A, PPP, unlike wortman-
nin (Wt), did not affect Akt phosphorylation in cells treated with
platelet-derived growth factor (PDGF). B, ERK phosphorylation
after 15 minutes was decreased by PPP in cells stimulated with
IGF-1, but not with PDGF.signaling mechanisms initiated by PDGF; however, thisdoes not exclude later effects mediated through increased
autocrine IGF-l synthesis.28,29
The cadherin:catenin complex recently has been impli-
cated in atherosclerosis and restenosis by regulating apo-
ptosis, migration, and proliferation in vascular SMCs.30
Because IGF-1 has been shown to affect location and
expression of catenin,31 the possibility for involvement of
cadherin:catenin in IGF-1R–dependent development of
restenosis can be raised. A potential regulatory link between
IGF-1R and catenin could be glycogen synthase kinase
3.32 Further studies to investigate the role of IGF-1R, as
well as effects of IGF-1R attenuation by specific inhibitors
such as PPP in this context, will be of interest.
Apoptosis has been shown to occur in restenotic lesions
in humans and is increased directly after angioplasty.33 A
balance between cell proliferation and apoptosis may there-
fore regulate the size of the neointima. IGF-l has been
shown to be important for survival in a number of cell types
through activation of the PI-3 kinase pathway.34-37 Our
data showing a trend in increased annexin V binding and
decreased Akt activation in PPP-treated SMCs supports the
role of IGF-l as a survival factor for SMCs. No significant
difference was found in annexin V binding between cells
treated with PPP and control cells, however, and we also
did not detect activated caspase 3 in early lesions from
PPP-treated animals. This suggests that the decrease in cell
numbers in vitro and decreased neointima formation dur-
ing PPP treatment cannot be primarily attributed to apo-
ptosis.
Although apoptosis has been demonstrated in the neo-
intima in the balloon rat carotid injury model, it is probably
most significant between 15 and 20 days after injury and
thus beyond the observed effects of PPP on intima devel-
opment in this study.38 However, because apoptosis has
been shown to account for some cell death directly after
balloon injury, we cannot exclude the possibility that PPP
may influence apoptosis at other time points than those
studied in this report.39
Growth hormone released in the pituitary gland stim-
ulates the production and release of IGF-1 locally in tissues.
Angiopeptin and octreotide are two somatostatin analogs
that down-regulate the production of growth hormone and
have therefore been used to target the growth hormone/
IGF-1 axis to prevent SMC proliferation and neointimal
formation.6 No clinical trials could show that octreotide or
angiopeptin had any beneficial effect, however.9,10 Other
investigators have used a more direct approach to target the
IGF-1 receptor. Hayry et al7 used an inhibitory stable
D-peptide analogue of IGF-1 to inhibit SMC replication
but were unable to significantly inhibit neointima forma-
tion in the rat carotid artery balloon injury model. In
another study, the carboxyl terminal end of IGF-1R was
truncated, and the dominant negative approach was suc-
cessful in suppressing neointimal formation.8
CONCLUSION
To our knowledge, this is the first study to show that
pharmacotherapy specifically targeting the IGF-l axis can
JOURNAL OF VASCULAR SURGERY
July 2007114 Razuvaev et alprevent neointimal hyperplasia. However, it is important to
mention that the role of IGF-l on the vasculature is contro-
versial. Although IGF-l may be detrimental for restenosis, it
may play an important role in plaque stabilization.40 There-
fore, a strategy aimed at local and time limited delivery of
the drug to sites prone to restenosis may have to be devel-
oped.
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